MethylGene's endeavors in the field of medicine may earn it a good look. The company is developing enzyme inhibitors to treat cancer and various infectious diseases. It develops product candidates for treatments for ailments such as solid tumors and hematological malignancies. MethylGene has also researched therapies to battle conditions including fungal infections and antibiotic resistance. The company forms licensing and collaboration agreements with other pharmaceutical firms to further its development programs.

Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company develops Zemiva, a molecular imaging pharmaceutical product, which completed Phase II clinical trail for the diagnosis of cardiac ischemia or insufficient blood flow to the heart; and Trofex, a preclinical trail product for the detection of metastatic prostate cancer. Its molecular radiotherapeutic oncology product candidates under development include Azedra that completed Phase I clinical trail for the treatment of pheochromocytoma in adults and neuroblastoma in children; Onalta, a Phase II clinical trail product for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors; and Solazed, a preclinical trail product for the treatment of malignant metastatic melanoma. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003.

ALK is a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. We are devoted to improving quality of life for people with allergies by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction.

NeurogesX, Inc. (NeurogesX) is a biopharmaceutical company focused on developing and commercializing pain management therapies. The Company is assembling a portfolio of pain management product candidates and is developing new therapies based on known chemical entities. Its initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company’s most advanced product candidate, Qutenza, a dermal patch containing a high concentration of synthetic capsaicin, is designed to manage pain associated with peripheral neuropathic pain conditions. The Company submitted to the United States Food and Drug Administration’s (FDA) an new drug application (NDA) for Qutenza for the management of pain associated with postherpetic neuralgia (PHN), in October 2008 which was filed by the FDA in December 2008. The Company's Products include Qutenza, NGX-1998, Acetaminophen Prodrugs (NGX-1576, NGX-9674, NGX-5752) and Opioid Prodrugs (NGX-6052).

Otsuka America is US headquarters of Japan's Otsuka Pharmaceutical. Otsuka America oversees pharmaceutical research and development, marketing, and distribution of both prescription drugs and over-the-counter (OTC) medicines. The holding company's pharmaceutical subsidiaries include Otsuka America Pharmaceutical (prescription drug marketing), Otsuka Maryland Medicinal Laboratories (research), Cambridge Isotope Laboratories (chemical ingredients), and Pharmavite (nutritionals). To help wash down its pills Otsuka America also holds consumer beverage makers Crystal Geyser (bottled water), Ridge Vineyards (wine), and Soma Beverage Company (specialty bottled water).

Grifols' focus is on producing plasma derivatives (plasma proteins for therapeutic use). This business generates about 70% of the group's annual revenue. Its diagnostic division manufactures devices, instrumentation, and reagents for clinical analysis labs, and markets products and equipment for blood banks. The third line of business, the hospital division, develops pharmaceutical products and medical devices used in hospital pharmacies. Clients include health care professionals and patients in more than 90 countries. Nearly three-quarters of Grifols' total sales come from international markets.

Morphotek has mighty morphin' power, but don't expect to find its products on the shelves of the local toy store. The biotechnology company develops monoclonal antibody (single-source protein) therapies for the treatment of cancer, inflammation, and infectious diseases using its proprietary Morphogenics technology platform. It conducts research and clinical development programs on its own drug candidates for ailments such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. Morphotek also enters collaborative research partnerships and licenses out its technology to other drug companies such as Amgen and Novo Nordisk. The company is a subsidiary of Eisai Inc., part of Japanese drug firm Eisai.

CEO Samuel Bogoch founded Oncolab shortly after he discovered the technology for detecting anti-malignin antibodies in the 1960s. Oncolab, Inc. company makes the AMAS test, an early warning blood screening test for cancer. The test detects abnormal levels of anti-malignin antibody which may indicate the presence of tumors. It is the first antibody that can be directly related to the survival of cancer patients and can be easily detected even before malignin reaches a detectable level. The test is shipped for free and is administered by doctors, then sent to Oncolab to process the results (for a fee); there are also a handful of lab locations that administer the test.

Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey. Cambrex Corporation, a life sciences company, provides products and services to develop and commercialize active pharmaceutical ingredients and advanced intermediates. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, and other custom chemicals derived from organic chemistry. The company sells its products through direct sales and independent agents to pharmaceutical and generic drug companies worldwide.

BioTime, Inc. company was founded in 1990 and is headquartered in Alameda, California. BioTime, Inc. is a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. The Company’s operating revenues have been generated primarily from licensing fees related to the sale of its plasma volume expander products, primarily Hextend. The company began to make its first stem cell research products available during the year ended December 31, 2008, but it had not yet generated significant revenues in that business segment.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.